Abstract |
The novel oral antiangiogenic agent TSU-68 was investigated in patients with metastatic breast cancer. Patients with anthracycline-pretreated metastatic breast cancer were randomly assigned to receive either TSU-68 400 mg twice daily on days 1-21 plus docetaxel 60 mg/m(2) on day 1 every 3 weeks, or docetaxel 60 mg/m(2) on day 1 every 3 weeks. The primary endpoint was progression-free survival. Between November 2006 and December 2007, 81 patients were included in this study (41 for TSU-68 plus docetaxel and 40 for docetaxel alone). Median progression-free survival was 6.8 months (95 % confidence interval [CI] = 5.4-12.5 months) in the TSU-68 plus docetaxel group and 8.1 months (95 % CI = 4.0-13.7 months) in the docetaxel-alone group (hazard ratio [HR] = 1.0; 95 % CI = 0.6-1.8; p = 0.95). There were no significant differences in the overall response rates and overall survival between groups (p = 0.29 and p = 0.42, respectively). In subgroup analysis, TSU-68 plus docetaxel was associated with better overall survival than docetaxel alone in anthracycline-resistant patients (HR = 0.3; 95 % CI = 0.1-0.8; p = 0.02). The most frequent adverse events were neutropenia and anorexia in both arms. Although both regimens were well tolerated, grade 3/4 non-hematologic toxicity was more frequently observed in the TSU-68 plus docetaxel group. Combination of TSU-68 and docetaxel is well tolerated but failed to demonstrate superior efficacy over docetaxel alone in anthracycline-pretreated breast cancer patients. As TSU-68 was associated with better survival in the anthracycline-resistant subgroup, it should be further explored in this subgroup.
|
Authors | Sung-Bae Kim, Changhoon Yoo, Jungsil Ro, Seock-Ah Im, Young-Hyuck Im, Jee Hyun Kim, Jin-Hee Ahn, Kyung Hae Jung, Hong Suk Song, Seok Yun Kang, Hee Sook Park, Hyun-Cheol Chung |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 32
Issue 4
Pg. 753-61
(Aug 2014)
ISSN: 1573-0646 [Electronic] United States |
PMID | 24715580
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Angiogenesis Inhibitors
- Anthracyclines
- Antineoplastic Agents
- Indoles
- Oxindoles
- Propionates
- Pyrroles
- Taxoids
- Docetaxel
- orantinib
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(administration & dosage, adverse effects)
- Anthracyclines
(therapeutic use)
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy)
- Disease-Free Survival
- Docetaxel
- Female
- Humans
- Indoles
(administration & dosage, adverse effects)
- Middle Aged
- Oxindoles
- Propionates
(administration & dosage, adverse effects)
- Pyrroles
- Taxoids
(administration & dosage, adverse effects)
|